{
    "clinical_study": {
        "@rank": "151371", 
        "arm_group": [
            {
                "arm_group_label": "NI-071", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Infliximab", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess equivalence of pharmacokinetics between NI-071 and\n      infliximab(the comparator) in Japanese healthy volunteers"
        }, 
        "brief_title": "Pharmacokinetics Study of NI-071", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subjects (healthy is defined as no clinically relevant abnormalities\n             identified by a detailed medical history, clinical laboratory tests, etc.)\n\n          2. Body Mass Index (BMI) of 18.5 to 25.0 kg/m2, and a total body weight of 50 to 80 kg\n\n        Exclusion Criteria:\n\n          1. Subjects with a following past History or concomitant diseases\n\n               -  Chronic or recurrent infectious disease\n\n               -  Demyelinating disease\n\n               -  Congestive heart failure\n\n               -  lymphoproliferative disorder or myelodysplastic syndrome\n\n               -  Malignancy\n\n               -  Interstitial lung disease\n\n          2. Subjects with active or latent tuberculosis or history of tuberculosis"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931189", 
            "org_study_id": "NI071A1"
        }, 
        "intervention": [
            {
                "arm_group_label": "NI-071", 
                "description": "100mg/vial", 
                "intervention_name": "NI-071", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Infliximab", 
                "description": "100mg/vial", 
                "intervention_name": "Infliximab", 
                "intervention_type": "Biological", 
                "other_name": "Remicade"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 8, 2013", 
        "location": {
            "contact": {
                "email": "mori@nichiiko.co.jp", 
                "last_name": "For site information, send an email with site number to"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "NichiIko Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Pharmacokinetics Study of NI-071", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PK : Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUCt)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931189"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK : Area Under the Curve From Time Zero Extrapolated to Infinite Time (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Safety : Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Safety : Incidence of Anti-Drug Antibodies(ADA)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Nichi-Iko Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nichi-Iko Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}